Breaking news on prostate
New Model May Simplify High-Dose Radiosurgery Planning published
Mon, 06 Sep 2010 00:00:00 PDT
There is yet no straightforward way to determine the optimal dose level and treatment schedules for high-dose radiation therapies such as stereotactic radiation therapy, which is used to treat brain and lung cancer, or for high-dose brachytherapy for prostate and other cancers. Radiation oncologists at the Ohio State University Comprehensive Cancer Center-Arthur G...
Light The White House Blue For Prostate Cancer Awareness Month published
Sat, 04 Sep 2010 02:00:00 PDT
Members of the Prostate Cancer Roundtable, consisting of America's Leading Prostate Cancer Organizations, are asking President Obama to place a blue ribbon on the White House and light the White House blue in the evenings in recognition of Prostate Cancer Awareness Month in September. This visible show of support for prostate cancer awareness by the White House will be a major tribute to the 2...
CyberKnife Treatment For Prostate Cancer published
Sat, 04 Sep 2010 01:00:00 PDT
CyberKnife radiosurgery treatment for prostate cancer is rapid, effective and has no side effects, with the added benefit of being non-invasive. Since 2003, the CyberKnife Center of Miami and the CyberKnife Center of Palm Beach have been providing this high tech cancer treatment longer than any facility in South Florida...
InSightec Treats First Prostate Cancer Patients In Clinical Trials published
Wed, 01 Sep 2010 02:00:00 PDT
nSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients. Seven patients with localized low-risk prostate cancer were treated worldwide so far...
Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients In Clinical Trials published
Wed, 01 Sep 2010 02:00:00 PDT
Elbit Imaging Ltd. (NASDAQ: EMITF) ("Elbit" "Company") that it's subsidiary, InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients...
Atrazine Causes Prostate Inflammation In Male Rats And Delays Puberty published
Fri, 27 Aug 2010 00:00:00 PDT
A new study shows that male rats prenatally exposed to low doses of atrazine, a widely used herbicide, are more likely to develop prostate inflammation and to go through puberty later than non-exposed animals. The research adds to a growing body of literature on atrazine, an herbicide predominantly used to control weeds and grasses in crops such as corn and sugar cane...
Prostate Cancer Treatment Expert Dr. David Samadi, MD Discusses Preventive Medicine Versus Treatment Or Outcome-Based Medicine published
Thu, 26 Aug 2010 03:00:00 PDT
Starting in September, President Obama's Affordable Care Act will go into effect. The act mandates free preventative services such as cholesterol or breast cancer screenings and tetanus shots...
Familial Prostate Cancer Risk Could Be Inflated By Increased Diagnosis Seeking published
Wed, 25 Aug 2010 02:00:00 PDT
A new study from Sweden suggests that the of risk of prostate cancer in men with a known family history of the disease could be inflated because such men are more likely to seek a diagnosis, further intensifying the controversial debate on whether PSA testing does more harm than good...
Cost Of Prostate Cancer Care Caries With Initial Treatment Choice published
Tue, 24 Aug 2010 04:00:00 PDT
A new analysis has found that short-term and long-term costs of prostate cancer care vary considerably based on which treatment strategy a man initially receives. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study finds that treatments that may be less expensive in the short-term may have higher long-term costs...
Cost Of Prostate Cancer Care Varies With Initial Treatment Choice published
Tue, 24 Aug 2010 01:00:00 PDT
A new analysis has found that short-term and long-term costs of prostate cancer care vary considerably based on which treatment strategy a man initially receives. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study finds that treatments that may be less expensive in the short-term may have higher long-term costs...
Brothers Of Prostate Cancer Patients Undergo More Diagnostic Activities published
Sat, 21 Aug 2010 00:00:00 PDT
The brothers of men with prostate cancer are at an increased risk of prostate cancer diagnosis because of increased diagnostic activity and not necessarily because they carry a genetic mutation that increases risk of the disease, according to a study published online August 19 in The Journal of the National Cancer Institute...
PCF To Host Patient, Survivor And Supporter Breakfast As Part Of The Advance On Washington For Prostate Cancer published
Thu, 19 Aug 2010 06:00:00 PDT
The Prostate Cancer Foundation (PCF) invites patients, survivors and prostate cancer supporters to attend a breakfast on September 14, 2010 at 8:45 a.m. in the Courtyard of The Washington Hilton. The event, designed to celebrate progress and survivorship, is being offered free of charge to the first 250 registrants...
Prostate Cancer Non-Profit Recognized For 20 Years Of Service published
Thu, 19 Aug 2010 03:00:00 PDT
The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy...
Loyola To Offer Free Exams As Part Of National Prostate Awareness Month In September published
Wed, 18 Aug 2010 03:00:00 PDT
More than 55 million American men are at risk for developing prostate cancer, according to the American Cancer Society. This year more than 27,000 men are expected to die of the disease, which is the second-leading cause of cancer death in men. "Fortunately, caught early enough prostate cancer is highly treatable," said urologist Dr. Robert C...
CRT And ValiRx Sign Licensing Deal To Develop Prostate Cancer Treatment published
Mon, 16 Aug 2010 03:00:00 PDT
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer. The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments...
Augmenix Announces First Commercial Use Of SpaceOAR™ System For Prostate-Rectum Separation In Prostate Cancer Patients published
Thu, 12 Aug 2010 03:00:00 PDT
Augmenix, Inc. announced that Prof. Michael Eble and Dr. Michael Pinkawa of the Aachen University Hospital, Aachen, Germany, performed a commercial implantation of the company's CE Mark approved SpaceOAR™ System. The SpaceOAR hydrogel (from spacing Organs At Risk) is designed to be a tissue compatible, absorbable spacer to reduce radiation injury to healthy tissues...
Severity Of Prostate Cancers Assessed Using Magnetic Resonance Imaging published
Thu, 12 Aug 2010 00:00:00 PDT
Rutgers researchers are developing methods that can accurately assess the severity of prostate cancer by analyzing magnetic resonance images and spectra of a patient's prostate gland...
Absolute And Relative Risk Of Cardiovascular Disease In Men With Prostate Cancer: Results From The Population-Based PCBaSe Sweden published
Wed, 11 Aug 2010 02:00:00 PDT
Androgen deprivation therapy (ADT) is reportedly associated with increased risks of diabetes, coronary artery disease, myocardial infarction (MI), sudden cardiac death, and stroke...
Induction Of Clusterin By AKT--Role In Cytoprotection Against Docetaxel In Prostate Tumor Cells published
Wed, 11 Aug 2010 01:00:00 PDT
In the online edition of Molecular Cancer Therapeutics, Dr. Bin Zhong and associates report a link between the signal transduction protein AKT and the androgen receptor chaperone protein clusterin (CLU). Two forms of CLU exist; one is secreted (sCLU) and the other localizes in the nucleus (nCLU). sCLU is associated with chemoresistance and overexpression of sCLU induces androgen resistance...
Inhibiting Prostate Cancer Without Disturbing Regular Body Processes published
Wed, 11 Aug 2010 00:00:00 PDT
A kinase is a type of enzyme the body uses to regulate the functions of the proteins required for cell growth and maintenance, and researchers have discovered that one in particular plays a key role in developing prostate cancer. "It's known as Mnk, and although it appears not to be essential for normal cell maintenance, it's important for cancer growth" said Dr...
CYP17 Polymorphisms And Prostate Cancer Outcomes published
Wed, 11 Aug 2010 00:00:00 PDT
CYP17 is an enzyme involved in androgen biosynthesis and recently has drawn attention as a target in castration-resistant prostate cancer (CRPC) where it is involved in intracrine androgen biosynthesis, despite androgen deprivation therapy. Abiraterone is a drug that targets CYP17A1 and is in phase III trials for CRPC...
A Comprehensive Panel Of Three-Dimensional Models For Studies Of Prostate Cancer Growth, Invasion And Drug Responses published
Tue, 10 Aug 2010 05:00:00 PDT
Prostate cancer (PrCa) cells form differentiated spheroids or "prostaspheres" in three-dimensional cell culture (3D culture) when embedded in extracellular matrix such as MatrigelTM, rat tail collagen, or hydrogel. While this has been pioneered and explored widely, e.g. in breast cancer, the characterization of prostate cancer cells in 3D culture has been seriously lagging behind...
Aragon Pharmaceuticals Doses First Patient In Phase 1/2 Clinical Trial Of ARN-509 For Castration-Resistant Prostate Cancer published
Tue, 10 Aug 2010 01:00:00 PDT
Aragon Pharmaceuticals announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC)...
Combodart® First Fixed Dose Combination Therapy For Treatment Of Benign Prostatic Hyperplasia (enlarged Prostate) Approved In Scotland published
Tue, 10 Aug 2010 00:00:00 PDT
GlaxoSmithKline (GSK) announced today that the Scottish Medicines Consortium (SMC) has accepted Combodart® (dutasteride 0.5mg/ tamsulosin hydrochloride 0.4mg) for use within NHS Scotland. Combodart is the first fixed dose combination of a 5-alpha reductase inhibitor, dutasteride and an alpha blocker, tamsulosin hydrochloride...
For Some Prostate Cancer, Surgery Is Better Than Radiation, Hormone Treatments published
Mon, 09 Aug 2010 01:00:00 PDT
Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF...
)
|
|
